October, 27 2026 Tuesday 20:48 Hrs
Last update 11-9-2025
  • SENSEX :   73,598.67

  • Top commodity trading and broking companies in India-8.08( -0.01%) 27-Oct-2026
Negative
Sensex 73598.67 -8.08  (-0.01) 27-Oct-2026
Previous Day Close 73606.75
Today's High/Low
High Low
  •  
  •  
73762.98 73179.41

Company News Details

Cipla Ltd
Industry :  Pharmaceuticals - Indian - Bulk Drugs & Formln
BSE Code
ISIN Demat
Book Value()
500087
INE059A01026
423.34903
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
CIPLA
33.33
109304.89
EPS(TTM)
Face Value()
Div & Yield %
40.59
2
0.96
 

Cipla and SBP Group sign exclusive license agreement for Rolditamig Deuderuxtecan
Aug 31,2026

Cipla and Sino Biopharmaceutical (HKEX: 1177) (SBP Group) today announced that SBP Group's subsidiary, Chia Tai Tianqing Pharmaceutical Group Co. (CTTQ), has entered into an exclusive license and supply agreement with Cipla for Rolditamig Deuderuxtecan, also known as TQB2102, a potential best-in-class HER2 bispecific antibody-drug conjugate (ADC).

Under this agreement, Cipla will receive exclusive rights to develop and commercialise TQB2102 in India, South Africa and 5 other emerging markets.

Cipla will be responsible for local clinical development, regulatory activities, and commercialisation in the licensed territories, while CTTQ will continue to manufacture and supply TQB2102.

TQB2102 is being evaluated across HER2-expressing cancers and has demonstrated encouraging clinical potential in HER2-low advanced breast cancer.

The collaboration brings together SBP Group's differentiated late-stage oncology asset and development and manufacturing capabilities with Cipla's established regulatory, medical, market access and commercial presence across India, South Africa, and other emerging markets.

Top

Attention Investor:

Prevent unauthorised transactions in your account Update your mobile numbers/email IDs with your stock brokers/Depository Participant.     KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, ,Mutual ).    No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account.